XML 33 R26.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Nature of Business - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Cash, cash equivalents and short-term investments $ 25,700    
Net income 130 $ (19,288)  
Accumulated deficit 145,934   $ 146,064
Acceleration of stock awards 10,500    
Severance and termination benefit expense 5,700    
Consideration Transferred 29,400    
Total operating expenses 5,767 22,340  
Fair value adjustment of warrant liability 5,590 1,146  
Non operating interest income 307 $ (116)  
Cash and cash equivalents 6,755   $ 5,530
Private Placement      
Gross proceeds from the private placement 20,400    
Net proceeds from private placement 19,000    
Commissions and other transaction expenses $ 1,400    
CalciMedica      
Percentage of ownership of common stock 72.00%    
Graybug      
Percentage of ownership of common stock 28.00%    
Convertible Debt [Member]      
Proceeds from issuance of convertible notes $ 8,600    
Preferred and Common stock [Member]      
Total net proceeds $ 131,600